RELAY THERAPEUTICS INC (RLAY) Fundamental Analysis & Valuation

NASDAQ:RLAY • US75943R1023

Current stock price

13.48 USD
+1.03 (+8.27%)
At close:
13.93 USD
+0.45 (+3.34%)
After Hours:

This RLAY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. RLAY Profitability Analysis

1.1 Basic Checks

  • In the past year RLAY has reported negative net income.
  • In the past year RLAY has reported a negative cash flow from operations.
  • In the past 5 years RLAY always reported negative net income.
  • In the past 5 years RLAY always reported negative operating cash flow.
RLAY Yearly Net Income VS EBIT VS OCF VS FCFRLAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M

1.2 Ratios

  • RLAY has a Return On Assets (-44.50%) which is comparable to the rest of the industry.
  • RLAY has a Return On Equity of -48.76%. This is in the better half of the industry: RLAY outperforms 63.25% of its industry peers.
Industry RankSector Rank
ROA -44.5%
ROE -48.76%
ROIC N/A
ROA(3y)-41.26%
ROA(5y)-37.26%
ROE(3y)-45.88%
ROE(5y)-41.75%
ROIC(3y)N/A
ROIC(5y)N/A
RLAY Yearly ROA, ROE, ROICRLAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -10 -20 -30 -40

1.3 Margins

  • RLAY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLAY Yearly Profit, Operating, Gross MarginsRLAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -5K -10K -15K -20K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. RLAY Health Analysis

2.1 Basic Checks

  • RLAY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, RLAY has more shares outstanding
  • The number of shares outstanding for RLAY has been increased compared to 5 years ago.
  • RLAY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RLAY Yearly Shares OutstandingRLAY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
RLAY Yearly Total Debt VS Total AssetsRLAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • RLAY has an Altman-Z score of 19.55. This indicates that RLAY is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 19.55, RLAY belongs to the top of the industry, outperforming 88.20% of the companies in the same industry.
  • RLAY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.55
ROIC/WACCN/A
WACC9.2%
RLAY Yearly LT Debt VS Equity VS FCFRLAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M 800M

2.3 Liquidity

  • RLAY has a Current Ratio of 22.61. This indicates that RLAY is financially healthy and has no problem in meeting its short term obligations.
  • RLAY has a Current ratio of 22.61. This is amongst the best in the industry. RLAY outperforms 96.52% of its industry peers.
  • RLAY has a Quick Ratio of 22.61. This indicates that RLAY is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 22.61, RLAY belongs to the top of the industry, outperforming 96.52% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 22.61
Quick Ratio 22.61
RLAY Yearly Current Assets VS Current LiabilitesRLAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. RLAY Growth Analysis

3.1 Past

  • RLAY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.22%, which is quite impressive.
  • The Revenue has grown by 53.45% in the past year. This is a very strong growth!
  • The Revenue for RLAY have been decreasing by -28.58% on average. This is quite bad
EPS 1Y (TTM)32.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.89%
Revenue 1Y (TTM)53.45%
Revenue growth 3Y123.25%
Revenue growth 5Y-28.58%
Sales Q2Q%N/A

3.2 Future

  • RLAY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.09% yearly.
  • The Revenue is expected to grow by 90.29% on average over the next years. This is a very strong growth
EPS Next Y-0.47%
EPS Next 2Y1.91%
EPS Next 3Y1.26%
EPS Next 5Y15.09%
Revenue Next Year-65.82%
Revenue Next 2Y20.39%
Revenue Next 3Y18.51%
Revenue Next 5Y90.29%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RLAY Yearly Revenue VS EstimatesRLAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
RLAY Yearly EPS VS EstimatesRLAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. RLAY Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RLAY. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RLAY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLAY Price Earnings VS Forward Price EarningsRLAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLAY Per share dataRLAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.91%
EPS Next 3Y1.26%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RLAY Dividend Analysis

5.1 Amount

  • No dividends for RLAY!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RLAY Fundamentals: All Metrics, Ratios and Statistics

RELAY THERAPEUTICS INC

NASDAQ:RLAY (4/7/2026, 8:00:01 PM)

After market: 13.93 +0.45 (+3.34%)

13.48

+1.03 (+8.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)04-30
Inst Owners80.84%
Inst Owner Change0%
Ins Owners1.23%
Ins Owner Change-1.73%
Market Cap2.41B
Revenue(TTM)15.36M
Net Income(TTM)-276.48M
Analysts87.78
Price Target17.43 (29.3%)
Short Float %13.62%
Short Ratio7.81
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.47%
Min EPS beat(2)-1.47%
Max EPS beat(2)22.41%
EPS beat(4)3
Avg EPS beat(4)11.69%
Min EPS beat(4)-1.47%
Max EPS beat(4)22.41%
EPS beat(8)7
Avg EPS beat(8)13.65%
EPS beat(12)10
Avg EPS beat(12)12.28%
EPS beat(16)12
Avg EPS beat(16)10.15%
Revenue beat(2)1
Avg Revenue beat(2)-30.9%
Min Revenue beat(2)-100%
Max Revenue beat(2)38.2%
Revenue beat(4)3
Avg Revenue beat(4)19032.2%
Min Revenue beat(4)-100%
Max Revenue beat(4)75184.3%
Revenue beat(8)4
Avg Revenue beat(8)11042.8%
Revenue beat(12)6
Avg Revenue beat(12)7898.75%
Revenue beat(16)7
Avg Revenue beat(16)5917.4%
PT rev (1m)17.5%
PT rev (3m)17.06%
EPS NQ rev (1m)-0.51%
EPS NQ rev (3m)10.97%
EPS NY rev (1m)0%
EPS NY rev (3m)3.77%
Revenue NQ rev (1m)414.29%
Revenue NQ rev (3m)1957.16%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-49.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 156.9
P/FCF N/A
P/OCF N/A
P/B 4.25
P/tB 4.25
EV/EBITDA N/A
EPS(TTM)-1.62
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-1.32
FCFYN/A
OCF(TTM)-1.32
OCFYN/A
SpS0.09
BVpS3.17
TBVpS3.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.5%
ROE -48.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-41.26%
ROA(5y)-37.26%
ROE(3y)-45.88%
ROE(5y)-41.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.53%
Cap/Sales 2.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.61
Quick Ratio 22.61
Altman-Z 19.55
F-Score5
WACC9.2%
ROIC/WACCN/A
Cap/Depr(3y)42.26%
Cap/Depr(5y)86.89%
Cap/Sales(3y)13%
Cap/Sales(5y)162.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.89%
EPS Next Y-0.47%
EPS Next 2Y1.91%
EPS Next 3Y1.26%
EPS Next 5Y15.09%
Revenue 1Y (TTM)53.45%
Revenue growth 3Y123.25%
Revenue growth 5Y-28.58%
Sales Q2Q%N/A
Revenue Next Year-65.82%
Revenue Next 2Y20.39%
Revenue Next 3Y18.51%
Revenue Next 5Y90.29%
EBIT growth 1Y18.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.16%
EBIT Next 3Y-1.56%
EBIT Next 5Y18.94%
FCF growth 1Y6.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.48%
OCF growth 3YN/A
OCF growth 5YN/A

RELAY THERAPEUTICS INC / RLAY Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for RELAY THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 4 / 10 to RLAY.


What is the valuation status for RLAY stock?

ChartMill assigns a valuation rating of 0 / 10 to RELAY THERAPEUTICS INC (RLAY). This can be considered as Overvalued.


How profitable is RELAY THERAPEUTICS INC (RLAY) stock?

RELAY THERAPEUTICS INC (RLAY) has a profitability rating of 1 / 10.


Can you provide the financial health for RLAY stock?

The financial health rating of RELAY THERAPEUTICS INC (RLAY) is 8 / 10.